Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-d318ddad4078d9629a42fcddbae8f64a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-d318ddad4078d9629a42fcddbae8f64a"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-d318ddad4078d9629a42fcddbae8f64a> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mpd318ddad4078d9629a42fcddbae8f64a"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mpd318ddad4078d9629a42fcddbae8f64a> ) ] ) . # <Composition/composition-en-d318ddad4078d9629a42fcddbae8f64a> a fhir:Composition ; fhir:id [ fhir:v "composition-en-d318ddad4078d9629a42fcddbae8f64a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-d318ddad4078d9629a42fcddbae8f64a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-d318ddad4078d9629a42fcddbae8f64a</b></p><a name=\"composition-en-d318ddad4078d9629a42fcddbae8f64a\"> </a><a name=\"hccomposition-en-d318ddad4078d9629a42fcddbae8f64a\"> </a><a name=\"composition-en-d318ddad4078d9629a42fcddbae8f64a-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1388/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - polivy</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1388/001" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mpd318ddad4078d9629a42fcddbae8f64a" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - polivy"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Polivy is and what it is used for</li><li>What you need to know before you are given Polivy</li><li>How Polivy is given</li><li>Possible side effects</li><li>How to store Polivy</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What polivy is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What polivy is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Polivy is</p><p>Polivy is a cancer medicine that contains the active substance polatuzumab vedotin .</p><p>It is always used together with other cancer medicines see below What other medicines is Polivy given with .</p><p>What Polivy is used for</p><p>Polivy is given to treat diffuse large B-cell lymphoma that has never been treated before.</p><p>Polivy is also given to treat diffuse large B-cell lymphoma that has come back or has not got better:</p><ul><li>after at least one previous therapy, and</li><li>when you cannot receive a stem cell transplant.</li></ul><p>Diffuse large B-cell lymphoma is a cancer that comes from B lymphocytes also called B-cells. These are a type of blood cells.</p><p>How Polivy works</p><p>Polivy contains something called a monoclonal antibody and a substance that can kill cancer called MMAE .</p><ul><li>The monoclonal antibody part of the medicine attaches to a target on B cells.</li><li>Once attached to B cells, the medicine releases MMAE into the B cells and kills them.</li></ul><p>What other medicines Polivy is given with</p><p>Polivy is given in combination with other cancer medicines:</p><ul><li>rituximab, cyclophosphamide, doxorubicin and prednisone for diffuse large B-cell lymphoma<br/>that has never been treated before.</li><li>rituximab and bendamustine for diffuse large B-cell lymphoma that has come back or has not got better, after at least one previous therapy and when you cannot receive a stem cell transplant.</li></ul></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take polivy" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take polivy" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You must not be given Polivy</p><ul><li>if you are allergic to polatuzumab vedotin or any of the other ingredients of this medicine (listed in section 6).</li><li>if you currently have an active severe infection. If the above applies to you, you must not be given Polivy. If you are not sure, talk to your doctor or nurse before you are given Polivy.</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or nurse before you are given Polivy if any of the following apply to you (or you are not sure):</p><ul><li>you have ever had brain or nerve problems such as:</li></ul><ul><li>memory problems</li><li>difficulty moving or sensations in your body such as feeling pins and needles, burning, pain and discomfort even from slight touch</li><li>eyesight problems</li></ul><ul><li>you have ever had liver problems</li><li>you think you have an infection or have had long-lasting or repeated infections such as herpes (see Infections in section 4)</li><li>you are due to have a vaccine or you know you may need to have one in the near future</li></ul><p>If any of the above apply to you (or you are not sure) talk to your doctor or nurse before you are given Polivy.</p><p>Pay attention to the following side effects</p><p>Polivy can cause some serious side effects that you need to tell your doctor or nurse about straight away. These include:</p><p>Myelosuppression</p><p>Myelosuppression is a condition in which the production of blood cells is decreased, resulting in fewer red blood cells, white blood cells, and platelets. Your doctor will do blood tests to check your blood cell count.</p><p>Tell your doctor or nurse straight away if you:</p><ul><li>develop chills or shivering</li><li>have a fever</li><li>have headaches</li><li>feel tired</li><li>feel dizzy</li><li>look pale</li><li>have unusual bleeding, bruising under the skin, bleeding longer than usual after your blood has been drawn, or bleeding from your gums.</li></ul><p>Peripheral neuropathy</p><p>Tell your doctor or nurse straight away if you have any problems with a change in the sensitivity of your skin, especially in your hands or feet, such as:</p><ul><li>numbness</li><li>tingling</li><li>a burning sensation</li><li>pain</li><li>discomfort or weakness</li><li>difficulty walking.</li></ul><p>If you had any of these symptoms before treatment with Polivy, tell your doctor straight away if you notice any changes in them.</p><p>If you have symptoms of peripheral neuropathy, your doctor may lower your dose.</p><p>Infections</p><p>Signs and symptoms of infections vary between individuals, tell your doctor or nurse straight away if you develop symptoms of an infection such as:</p><ul><li>fever</li><li>cough</li><li>chest pain</li><li>tiredness</li><li>painful rash</li><li>sore throat</li><li>burning pain when passing urine</li><li>feeling weak or generally unwell.</li></ul><p>Progressive multifocal leukoencephalopathy (PML)</p><p>PML is a very rare and life threatening infection in the brain, that has occured in one patient treated with Polivy together with bendamustine and another medicine called obinutuzumab.</p><p>Tell your doctor or nurse straight away if you have:</p><ul><li>memory loss</li><li>trouble speaking</li><li>difficulty walking</li><li>problems with your eyesight.</li></ul><p>If you had any of these symptoms before treatment with Polivy, tell your doctor straight away if you notice any changes in them. You may need medical treatment.</p><p>Tumour lysis syndrome</p><p>Some people may develop unusual levels of some substances (such as potassium and uric acid) in the blood caused by the fast breakdown of cancer cells during treatment. This is called tumour lysis syndrome . Your doctor, pharmacist or nurse will do blood tests to check for the condition.</p><p>Infusion-related reactions</p><p>Infusion-related reactions, allergic or anaphylactic (more severe allergic) reactions can happen. Your doctor or nurse will check for side effects during your infusion and for 30 to 90 minutes afterwards. If you get any serious reaction, your doctor may stop treatment with Polivy.</p><p>Liver damage</p><p>This medicine can cause inflammation or damage to cells in the liver that affect the normal function of the liver. Injured liver cells may leak high amounts of certain substances (liver enzymes and bilirubin) into the bloodstream, which can be detected by blood tests.</p><p>In most cases you will not have any symptoms but tell your doctor or nurse straight away if you get:</p><ul><li>yellowing of your skin and of the whites of your eyes (jaundice).</li></ul><p>Your doctor will check your blood to test your liver function before and regularly during treatment.</p><p>Children and adolescents</p><p>This medicine should not be used in children or young people under the age of 18. This is because there is no information about its use in this age group.</p><p>Other medicines and Polivy</p><p>Other medicines and vaccines</p><p>Tell your doctor or nurse if you are taking, have recently taken or might start taking any other medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p>Also tell your doctor or nurse if you are due to have a vaccine or you know you may need to have one in the near future.</p><p>Contraception (women and men)</p><p>If you are a woman of childbearing age, you must use effective contraception during treatment and for 9 months after the last dose of Polivy.</p><p>Men must use contraception during treatment and for 6 months after the last dose of Polivy.</p><p>Pregnancy</p><p>It is important to tell your doctor before and during treatment if you are pregnant, think you may be pregnant, or are planning to get pregnant. This is because Polivy can affect your baby s health.</p><p>Do not use this medicine if you are pregnant unless you and your doctor decide that the benefit to you outweighs possible risk to the unborn baby.</p><p>Breast-feeding</p><p>Do not breast-feed while receiving Polivy and for at least 3 months after the last dose, because small amount of Polivy may pass into your breast milk.</p><p>Fertility</p><p>Men are advised to have sperm samples preserved and stored before treatment with this medicine.</p><p>Driving and using machines</p><p>Polivy has a minor influence on your ability to drive, cycle or use any tools or machines.</p><ul><li>If you get infusion-related reactions or nerve damage, or if you feel tired, weak or dizzy (see section 4) do not drive, cycle or use tools or machines until the reaction stops.</li></ul><p>See section 4 for more information about side effects.</p><p>Polivy contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take polivy" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take polivy" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Polivy is given under the supervision of a doctor experienced in giving such treatments.</p><p>It is given into a vein, as a drip over 90 minutes.</p><p>How much Polivy is given</p><p>The dose of this medicine depends on your body weight.</p><ul><li>The usual starting dose is 1.8 mg for each kilogram of your body weight.</li><li>If you have peripheral neuropathy, your doctor may lower your dose.</li></ul><p>How often is Polivy given?</p><ul><li>Each cycle lasts 21 days.</li><li>You will be given 6 treatment cycles of Polivy in combination with other medicines.</li></ul><p>What other medicines is Polivy given with?</p><ul><li>rituximab, cyclophosphamide, doxorubicin and prednisone for diffuse large B-cell lymphoma<br/>that has never been treated before or,</li><li>rituximab and bendamustine for diffuse large B-cell lymphoma that has come back or has not got better, after at least one previous therapy and when you cannot receive a stem cell transplant.</li></ul><p>If you miss a dose of Polivy</p><ul><li>If you miss an appointment, make another one straight away.</li><li>For the treatment to be fully effective, it is very important not to miss a dose.</li></ul><p>If you stop receiving Polivy</p><p>Do not stop treatment with Polivy unless you have discussed this with your doctor. This is because stopping treatment may make your condition worse.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported with this medicine:</p><p>Serious side effects</p><p>Tell your doctor or nurse straight away if you notice any of the following serious side effects you may need urgent medical treatment. These may be new symptoms or a change in your current symptoms.</p><ul><li>infusion-related reactions your doctor will check for these for 30-90 minutes afterwards</li><li>fevers and chills</li><li>rash/hives</li><li>severe infections</li><li>pneumonia (lung infection)</li><li>herpes infection</li><li>viral infections</li><li>upper respiratory tract infection</li><li>skin infection</li><li>urinary tract infection</li><li>unusual bleeding or bruising under the skin</li><li>memory loss, trouble speaking, difficulty walking or problems with your eyesight</li><li>yellowing of skin or whites of your eyes</li><li>breathlessness and difficulty in breathing</li></ul><p>Other side effects</p><p>Tell your doctor or nurse if you notice any of the following side effects:</p><p>Very common: may affect more than 1 in 10 people</p><ul><li>pneumonia (lung infection)</li><li>runny nose, sneezing, sore throat and cough (upper respiratory tract infection)</li><li>numbness, tingling, a burning sensation, pain, discomfort or weakness and/or difficulty walking (peripheral neuropathy)</li><li>fever</li><li>cough</li><li>vomiting</li><li>diarrhoea or constipation</li><li>soreness or inflammation of the mouth and/or gut (mucositis)</li><li>feeling sick (nausea)</li><li>abdominal (belly) pain</li><li>feeling tired</li><li>not feeling hungry</li><li>loss of weight</li><li>infusion-related reactions</li><li>common cold</li><li>hair loss</li><li>changes in blood tests:</li></ul><ul><li>low levels of all types of white blood cell (combined)</li><li>low levels of neutrophils (a type of white blood cell) with or without fever</li><li>low level of platelets (a type of blood cell that helps your blood to clot)</li><li>low levels of red blood cells (anaemia)</li><li>low level of potassium in the blood (hypokalaemia)</li></ul><p>Common: may affect up to 1 in 10 people</p><ul><li>severe infection (sepsis)</li><li>urinary tract infection</li><li>viral infections</li><li>herpes infection</li><li>skin infections</li><li>inflammation of the lungs</li><li>breathlessness and difficulty in breathing</li><li>dizziness</li><li>fluid retention causing swelling in the lower legs or hands (oedema peripheral)</li><li>high level of transaminases in the blood</li><li>joint pain</li><li>itchiness</li><li>chills</li><li>rash</li><li>dry skin</li><li>muscle pain</li><li>changes shown in blood tests:</li></ul><ul><li>decreased number of all blood cells (pancytopenia)</li><li>low levels of lymphocytes (a type of white blood cells)</li><li>low level of phosphate in the blood (hypophosphataemia)</li><li>low level of calcium in the blood (hypocalcaemia)</li><li>low level of albumin in the blood (hypoalbuminemia)</li><li>high level of lipase enzyme in the blood</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>blurred vision</li></ul><p>Tell your doctor or nurse straight away if you notice any of the side effects listed above.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store polivy" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store polivy" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Polivy will be stored by the healthcare professionals at the hospital or clinic. The storage details are as follows:</p><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.</li><li>Store in a refrigerator (2 8 ).</li><li>Do not freeze.</li><li>Keep the container in the outer carton in order to protect from light.</li></ul><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Polivy contains</p><ul><li>The active substance is polatuzumab vedotin.</li><li>Polivy 30 mg: Each vial contains 30 milligrams (mg) polatuzumab vedotin.</li><li>Polivy 140 mg: Each vial contains 140 milligrams (mg) polatuzumab vedotin.</li><li>After reconstitution each millilitre (mL) contains 20 mg polatuzumab vedotin.</li><li>The other ingredients are: succinic acid, sodium hydroxide, sucrose, polysorbate 20. See section Polivy contains sodium .</li></ul><p>What Polivy looks like and contents of the pack</p><p>Polivy powder for concentrate for solution for infusion is a white to slightly greyish-white cake provided in a glass vial.</p><p>Each pack of Polivy consists of one vial.</p><p>Marketing Authorisation Holder</p><p>Roche Registration GmbH<br/>Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>Manufacturer</p><p>Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien N.V. Roche S.A. T l/Tel: +32 (0) 2 525 82 Lietuva UAB Roche Lietuva<br/>Tel: +370 5 2546</p><p>: +359 2 818 44 Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)</p><p>esk republika Roche s. r. o. Tel: +420 - 2 20382Magyarorsz g Roche (Magyarorsz g) Kft. Tel: +36 - 1 279 4Danmark Roche Pharmaceuticals A/S</p><p>Tlf: +45 - 36 39 99 Malta Irreferi g all-Irlanda<br/>Deutschland Roche Pharma AG Tel: +49 (0) 7624 Nederland Roche Nederland B.V. Tel: +31 (0) 348 438Eesti Roche Eesti O<br/>Tel: + 372 - 6 177 Norge Roche Norge AS Tlf: +47 - 22 78 90<br/>Roche (Hellas) A.E. : +30 210 61 66 sterreich Roche Austria GmbH Tel: +43 (0) 1 27Espa a Roche Farma S.A. Tel: +34 - 91 324 81 Polska Roche Polska Sp.z o.o. Tel: +48 - 22 345 18 France Roche T l: +33 (0) 1 47 61 40 Portugal Roche Farmac utica Qu mica, Lda Tel: +351 - 21 425 70 Hrvatska Roche d.o.o. Tel: +385 1 4722 Rom nia Roche Rom nia S.R.L. Tel: +40 21 206 47 Ireland Roche Products (Ireland) Ltd. Tel: +353 (0) 1 469 0Slovenija Roche farmacevtska dru ba d.o.o. Tel: +386 - 1 360 26 sland Roche Pharmaceuticals A/S</p><p>c/o Icepharma hf S mi: +354 540 8Slovensk republika Roche Slovensko, s.r.o. Tel: +421 - 2 52638Italia Roche S.p.A. Tel: +39 - 039 2Suomi/Finland Roche Oy Puh/Tel: +358 (0) 10 554<br/>. . & . : +357 - 22 76 62 Sverige Roche AB Tel: +46 (0) 8 726 1Latvija Roche Latvija SIA Tel: +371 - 6 7039United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366This leaflet was last revised in {MM/YYYY}</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mpd318ddad4078d9629a42fcddbae8f64a> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mpd318ddad4078d9629a42fcddbae8f64a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpd318ddad4078d9629a42fcddbae8f64a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpd318ddad4078d9629a42fcddbae8f64a</b></p><a name=\"mpd318ddad4078d9629a42fcddbae8f64a\"> </a><a name=\"hcmpd318ddad4078d9629a42fcddbae8f64a\"> </a><a name=\"mpd318ddad4078d9629a42fcddbae8f64a-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1388/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Polivy 30 mg powder for concentrate for solution for infusion.</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1388/001" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "Polivy 30 mg powder for concentrate for solution for infusion." ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
